937189-29-2

Upstream product

• 937189-28-1 6-(5-bromo-2-trifluoromethyl-phenyl)-4-(3,5-dimethyl-phenyl)-1,2,3,6-tetrahydro-pyrrolo[2,3-d]pyridazin-7-one 
• 96-32-2 bromoacetic acid methyl ester 

Downstream Products

• 937189-30-5 methyl [6-[5-((R)-3-acetylamino-pyrrolidin-1-yl)-2-trifluoromethyl-phenyl]-4-(3,5-dimethyl-phenyl)-7-oxo-2,3,6,7-tetrahydro-pyrrolo[2,3-d]pyridazin-1-yl]-acetate 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUND AND MEDICINAL APPLICATION THEREOF

The present invention aims at providing a novel heterocyclic compound having HCV entry inhibitory activity and the pharmaceutical use thereof. The present invention provides a therapeutic agent for hepatitis C comprising a heterocyclic compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof as an active ingredient: wherein Q1 is -N=, etc., Q2 is -N-, etc., Q3 is -N=, etc., Q4 is -N-, etc., Q5 is -N-, etc., R1 is a hydrogen atom, etc., R2 is a hydrogen atom, etc., ring A is a monocyclic aryl group optionally having substituent(s), etc., and ring B is a monocyclic aryl group optionally having substituent(s), etc.